{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:02:10Z","timestamp":1789970530931,"version":"4.0.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oxiracetam is used in China for cognitive dysfunction after traumatic brain injury (TBI), but its efficacy and safety remain uncertain. We assessed oxiracetam in adults with acute TBI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched six bibliographic databases and trial registries from inception through 28 February 2026, for randomized trials. Risk of bias was assessed with the Cochrane risk-of-bias tool (RoB 1), and evidence certainty with GRADE. We performed comparator-stratified random-effects meta-analyses and verified treatment regimens, assessment times, and numerical data against source reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-three randomized controlled trials involving 2,864 participants contributed to the quantitative synthesis. When both groups received the same or otherwise balanced background therapy, mean post-treatment MMSE scores were 4.67 points higher with oxiracetam (10 studies, n = 798; MD 4.67, 95% CI 3.07\u20136.28; I\n                      <jats:sup>2<\/jats:sup>\n                      = 92%), and NIHSS scores were 3.22 points lower (8 studies, n = 685; MD \u22123.22, 95% CI \u22124.14 to \u22122.30; I\n                      <jats:sup>2<\/jats:sup>\n                      = 58%). Compared with piracetam, mean post-treatment MMSE scores were 4.05 points higher with oxiracetam (8 studies, n = 739; MD 4.05, 95% CI 3.51\u20134.60; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). These MDs were between-group differences in endpoint scores, not within-patient changes. Barthel Index and GCS scores were also higher with oxiracetam in balanced-background comparisons, but heterogeneity was substantial. More participants met study-defined response criteria with oxiracetam than with control (5 studies, n = 558; RR 1.26, 95% CI 1.16\u20131.37; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). In balanced-background comparisons, reported adverse events or adverse reactions did not differ significantly between groups (5 studies, n = 504; RR 1.14, 95% CI 0.64\u20132.04; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%), although reporting was sparse and incomplete.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Oxiracetam was associated with higher short-term MMSE scores and, in some comparisons, lower NIHSS scores and higher Barthel Index and GCS scores after acute TBI. Risk of bias, clinical heterogeneity, variable assessment timing, incomplete safety reporting, and low or very low certainty of evidence preclude firm conclusions about durable benefit or routine clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD420261394733<\/jats:ext-link>\n                      , identifier CRD420261394733.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1894256","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:17Z","timestamp":1789968917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of oxiracetam for cognitive and functional outcomes after acute traumatic brain injury in Chinese populations: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Mimi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Zhejiang Chinese Medical University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Zhejiang Chinese Medical University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangxuan","family":"Shou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Zhejiang Chinese Medical University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jueyi","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Zhejiang Chinese Medical University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.16281\/j.cnki.jocml.2015.26.120","article-title":"Effect analysis of oxiracetam for craniocerebral injury","volume":"2","author":"Bai","year":"2015","journal-title":"J. Clin. Med. Lit."},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/HTR.0000000000000838","article-title":"INCOG 2.0 guidelines for cognitive rehabilitation following traumatic brain injury: methods, overview, and principles","volume":"38","author":"Bayley","year":"2023","journal-title":"J. Head. Trauma Rehabil."},{"key":"B3","doi-asserted-by":"publisher","first-page":"16084","DOI":"10.1038\/nrdp.2016.84","article-title":"Traumatic brain injuries","volume":"2","author":"Blennow","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3969\/j.issn.1674-4721.2012.15.030","article-title":"Clinical efficacy and safety of injectable oxiracetam for craniocerebral injury with neurological deficit. China Mod","volume":"19","author":"Chen","year":"2012","journal-title":"Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.16659\/j.cnki.1672-5654.2014.31.063","article-title":"Efficacy of oxiracetam for traumatic brain injury","volume":"11","author":"Chen","year":"2014","journal-title":"China Health Ind."},{"key":"B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.19577\/j.1007-4406.2020.01.004","article-title":"Effects of oxiracetam in patients with severe craniocerebral injury","volume":"29","author":"Cheng","year":"2020","journal-title":"Chin. J. Clin. Pharm."},{"key":"B7","unstructured":"Expert consensus on early rehabilitation management of severe traumatic brain injury in China\n          \n          1615\n          1623\n          10.3760\/cma.j.issn.0376-2491.2017.21.006\n          Natl. Med. J. China\n          97\n          2017"},{"key":"B8","volume-title":"Review Manager 5 (RevMan 5) [computer program], version 5.4.1","year":"2020"},{"key":"B9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials. Control","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Clin. Trials"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3171\/2017.10.JNS17352","article-title":"Estimating the global incidence of traumatic brain injury","volume":"130","author":"Dewan","year":"2019","journal-title":"J. Neurosurg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3969\/j.issn.1008-5971.2013.09.040","article-title":"Effects of oxiracetam injection on neurological deficit, memory, and intellectual impairment after moderate traumatic brain injury","volume":"21","author":"Duan","year":"2013","journal-title":"Pract. J. Card. Cereb. Pneum. Vasc. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10143-016-0775-y","article-title":"A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury","volume":"41","author":"El Sayed","year":"2018","journal-title":"Neurosurg. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3969\/j.issn.1673-5110.2016.08.084","article-title":"Efficacy of oxiracetam for neurological deficit caused by craniocerebral injury","volume":"19","author":"Fan","year":"2016","journal-title":"Chin. J. Pract. Nerv. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/0165-0173(94)90011-6","article-title":"Piracetam and other structurally related nootropics","volume":"19","author":"Gouliaev","year":"1994","journal-title":"Brain Res. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3969\/j.issn.1674-4721.2009.19.026","article-title":"Clinical study of oxiracetam injection in moderate-to-severe acute brain injury","volume":"16","author":"Guo","year":"2009","journal-title":"China Mod. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.13210\/j.cnki.jhmu.20150313.003","article-title":"Effect of oxiracetam on tumor necrosis factor-\u03b1 in patients with severe traumatic brain injury","volume":"21","author":"Guo","year":"2015","journal-title":"J. Hainan Med. Univ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3969\/j.issn.1673-5110.2016.05.026","article-title":"Effect of oxiracetam on serum inflammatory mediators in patients with severe traumatic brain injury","volume":"19","author":"Guo","year":"2016","journal-title":"Chin. J. Pract. Nerv. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3969\/j.issn.1005-9202.2012.10.080","article-title":"Efficacy of oxiracetam in older patients with severe traumatic brain injury","volume":"32","author":"Huang","year":"2012","journal-title":"Chin. J. Gerontol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.19435\/j.1672-1721.2016.25.024","article-title":"Randomized controlled study of oxiracetam plus nimodipine in severe cerebral contusion and laceration","volume":"20","author":"Liang","year":"2016","journal-title":"Med. Forum"},{"key":"B22","first-page":"97","article-title":"Clinical effects of oxiracetam in craniocerebral injury","volume":"24","author":"Liu","year":"2012","journal-title":"Strait Pharm. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3969\/j.issn.1672-8351.2018.08.105","article-title":"Efficacy of oxiracetam injection for acute craniocerebral injury","volume":"15","author":"Liu","year":"2018","journal-title":"J. North. Pharm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.15932\/j.0253-9713.2020.10.020","article-title":"Clinical effects of oxiracetam injection in older patients with craniocerebral injury","volume":"42","author":"Liu","year":"2020","journal-title":"Beijing Med. J."},{"key":"B25","first-page":"65","article-title":"Clinical observation of oxiracetam in 25 patients with craniocerebral injury","volume":"23","author":"Liu","year":"2014","journal-title":"Chin. J. Ethnomed. Ethnopharm."},{"key":"B26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41392-025-02492-5","article-title":"Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trial","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S1474-4422(17)30371-X","article-title":"Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research","volume":"16","author":"Maas","year":"2017","journal-title":"Lancet Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S1474-4422(22)00309-X","article-title":"Traumatic brain injury: progress and challenges in prevention, clinical care, and research","volume":"21","author":"Maas","year":"2022","journal-title":"Lancet Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3969\/j.issn.1006-5687.2022.03.004","article-title":"Effect of oxiracetam on rescue outcomes in patients with acute severe craniocerebral injury and traumatic shock","volume":"34","author":"Qi","year":"2022","journal-title":"Tianjin Pharm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3760\/cma.j.issn.1671-8925.2005.05.014","article-title":"Clinical evaluation of oxiracetam in the treatment of craniocerebral trauma","volume":"4","author":"Shu","year":"2005","journal-title":"Chin. J. Neuromed."},{"key":"B32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.7501\/j.issn.1674-5515.2015.02.016","article-title":"Clinical Observation Of Oxiracetam combined with nimodipine in severe cerebral contusion and laceration","volume":"30","author":"Si","year":"2015","journal-title":"Drug Clin."},{"key":"B33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.11915\/j.issn.1671-5403.2019.12.187","article-title":"Clinical effects of oxiracetam injection and its effects on inflammation and oxidative stress in older patients with craniocerebral injury","volume":"18","author":"Sui","year":"2019","journal-title":"Chin. J. Mult. Organ Dis. Elder."},{"key":"B34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3969\/j.issn.1674-4985.2012.09.088","article-title":"Efficacy of oxiracetam injection in acute craniocerebral injury","volume":"9","author":"Sun","year":"2012","journal-title":"Med. Innov. China"},{"key":"B35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.19613\/j.cnki.1671-3141.2018.74.095","article-title":"Effect of Oxiracetam Combined With nimodipine in severe cerebral contusion and laceration","volume":"18","author":"Sun","year":"2018","journal-title":"World Latest Med. Inf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3969\/j.issn.1671-945X.2020.09.047","article-title":"Effect of oxiracetam combined with hyperbaric oxygen on prognosis after craniocerebral trauma","volume":"18","author":"Tan","year":"2020","journal-title":"J. China Prescr. Drug"},{"key":"B37","volume-title":"VA\/DoD Clinical Practice Guideline for the Management and Rehabilitation of Post-Acute Mild Traumatic Brain Injury, Version 3.0","year":"2021"},{"key":"B38","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/cpt.3186","article-title":"Pharmacotherapy to improve cognitive functioning after acquired brain injury: a meta-analysis and meta-regression","volume":"115","author":"van der Veen","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3969\/j.issn.1674-4055.2016.02.09","article-title":"Systematic review on curative effects of oxiracetam and piracetam in treatment of cerebral organic syndrome","volume":"8","author":"Wang","year":"2016","journal-title":"Chin. J. Evid.-Based Cardiovasc. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.2096-3327.2018.07.001","article-title":"Efficacy of oxiracetam for cognitive impairment after moderate traumatic brain injury","volume":"15","author":"Wang","year":"2018","journal-title":"Chin. J. Ration. Drug Use"},{"key":"B41","first-page":"1222","article-title":"Clinical observation of oxiracetam for craniocerebral injury","volume":"35","author":"Wu","year":"2014","journal-title":"Jilin Med. J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"344","DOI":"10.14010\/j.cnki.wjyx.2013.04.014","article-title":"Efficacy of oxiracetam in severe craniocerebral injury","volume":"24","author":"Yang","year":"2013","journal-title":"Med. J. Chin. People's Armed Police Forces"},{"key":"B43","doi-asserted-by":"publisher","first-page":"100005","DOI":"10.1016\/j.jnrt.2022.100005","article-title":"Guideline of clinical neurorestorative treatment for brain trauma (2022 China version)","volume":"10","author":"Yang","year":"2022","journal-title":"J. Neurorestoratol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.15912\/j.cnki.gocm.2014.13.191","article-title":"Clinical efficacy of oxiracetam in older patients with severe craniocerebral injury","volume":"12","author":"Yin","year":"2014","journal-title":"Guide China Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00701-023-05674-8","article-title":"Oxiracetam alleviates anti-inflammatory activity and ameliorates cognitive impairment in the early phase of traumatic brain injury","volume":"165","author":"Youn","year":"2023","journal-title":"Acta Neurochir."},{"key":"B46","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3969\/j.issn.1671-2897.2005.04.026","article-title":"Clinical study of oxiracetam for cognitive impairment after moderate-to-severe brain injury","volume":"4","author":"Yu","year":"2005","journal-title":"Chin. J. Neurosurg. Dis. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.14163\/j.cnki.11-5547\/r.2021.30.036","article-title":"Effect of oxiracetam combined with nimodipine in severe cerebral contusion and laceration","volume":"16","author":"Yun","year":"2021","journal-title":"China Pract. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3969\/j.issn.1672-3511.2015.06.011","article-title":"Clinical study of oxiracetam in acute craniocerebral injury","volume":"27","author":"Zhai","year":"2015","journal-title":"Med. J. West China"},{"key":"B49","doi-asserted-by":"publisher","first-page":"500","DOI":"10.20282\/j.cnki.1006-4141.2018.06.008","article-title":"Effect of oxiracetam on neurological function and serum inflammatory factors in patients with severe traumatic brain injury","volume":"39","author":"Zhai","year":"2018","journal-title":"Yunnan Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3969\/j.issn.1007-614X.2017.3.13","article-title":"Clinical observation of oxiracetam combined with nimodipine in severe cerebral contusion and laceration","volume":"33","author":"Zhang","year":"2017","journal-title":"Chin. Community Dr."},{"key":"B51","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3969\/j.issn.1671-2897.2008.02.023","article-title":"Clinical evaluation of oxiracetam for neurological deficit after moderate-to-severe traumatic brain injury","volume":"7","author":"Zhang","year":"2008","journal-title":"Chin. J. Neurosurg. Dis. Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3969\/j.issn.1006-4931.2013.15.041","article-title":"Oxiracetam as adjunctive therapy in 48 patients with acute craniocerebral injury","volume":"22","author":"Zhou","year":"2013","journal-title":"China Pharm."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1894256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:43Z","timestamp":1789968943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1894256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":52,"alternative-id":["10.3389\/fphar.2026.1894256"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1894256","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1894256"}}